

Antonio Dono

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6243756/publications.pdf>

Version: 2024-02-01

35
papers

308
citations

1039880

9
h-index

1058333

14
g-index

35
all docs

35
docs citations

35
times ranked

300
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Glioma and temozolomide induced alterations in gut microbiome. <i>Scientific Reports</i> , 2020, 10, 21002. | 1.6 | 38 |
| 2 | Molecular characteristics and clinical features of multifocal glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 389-397. | 1.4 | 25 |
| 3 | Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics. <i>Journal of Clinical Neuroscience</i> , 2020, 82, 1-8. | 0.8 | 22 |
| 4 | PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 153, 153-160. | 1.4 | 20 |
| 5 | Glioma induced alterations in fecal short-chain fatty acids and neurotransmitters. <i>CNS Oncology</i> , 2020, 9, CNS57. | 1.2 | 19 |
| 6 | Differences in Genomic Alterations Between Brain Metastases and Primary Tumors. <i>Neurosurgery</i> , 2021, 88, 592-602. | 0.6 | 19 |
| 7 | IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions. <i>Current Oncology Reports</i> , 2021, 23, 20. | 1.8 | 18 |
| 8 | Landscape of Genomic Alterations in <i>IDH</i> Wild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic Factor. <i>JCO Precision Oncology</i> , 2020, 4, 575-584. | 1.5 | 15 |
| 9 | Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors. <i>Scientific Reports</i> , 2020, 10, 14326. | 1.6 | 14 |
| 10 | Immunotyping of tumorâ€infiltrating lymphocytes in tripleâ€negative breast cancer and genetic characterization. <i>Oncology Letters</i> , 2020, 20, 1-1. | 0.8 | 12 |
| 11 | Extent of resection and survival outcomes of geriatric patients with glioblastoma: Is there benefit from aggressive surgery?. <i>Clinical Neurology and Neurosurgery</i> , 2021, 202, 106474. | 0.6 | 11 |
| 12 | Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. <i>Journal of Neuro-Oncology</i> , 2020, 149, 463-472. | 1.4 | 10 |
| 13 | Glioma and the gutâ€brain axis: opportunities and future perspectives. <i>Neuro-Oncology Advances</i> , 2022, 4, vda054. | 0.4 | 10 |
| 14 | Treatment trends and overall survival in patients with grade II/III ependymoma: The role of tumor grade and location. <i>Clinical Neurology and Neurosurgery</i> , 2020, 199, 106282. | 0.6 | 9 |
| 15 | Comparative Analysis of Survival Outcomes and Prognostic Factors of Supratentorial versus Cerebellar Glioblastoma in the Elderly: Does Location Really Matter?. <i>World Neurosurgery</i> , 2021, 146, e755-e767. | 0.7 | 7 |
| 16 | Increased Risk of Subsequent Meningioma Among Women with Malignant Breast Cancer. <i>World Neurosurgery</i> , 2020, 139, e271-e285. | 0.7 | 6 |
| 17 | Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. <i>World Neurosurgery</i> , 2021, 149, e894-e912. | 0.7 | 5 |
| 18 | Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 153-162. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The role of <i>RB1</i> alteration and 4q12 amplification in IDH-WT glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab050. | 0.4 | 5 |
| 20 | Predictors of outcome in pleomorphic xanthoastrocytoma. <i>Neuro-Oncology Practice</i> , 2021, 8, 222-229. | 1.0 | 5 |
| 21 | Metastatic Neoplasm Volume Kinetics Following 2-Stage Stereotactic Radiosurgery. <i>World Neurosurgery</i> , 2022, 161, e210-e219. | 0.7 | 5 |
| 22 | Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?. <i>Journal of Neuro-Oncology</i> , 2021, 152, 163-172. | 1.4 | 4 |
| 23 | Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas. , 2021, 40, 98-107. | | 4 |
| 24 | Early repeat resection for residual glioblastoma: decision-making among an international cohort of neurosurgeons. <i>Journal of Neurosurgery</i> , 2022, 137, 1618-1627. | 0.9 | 4 |
| 25 | Real-time intracranial pressure monitoring during high-dose methotrexate treatment for primary central nervous system lymphoma. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100234. | 0.7 | 3 |
| 26 | Endoscopic Third Ventriculostomy for Hydrocephalus Secondary to Extraventricular Obstruction in Thalamic Hemorrhage: A Case Series. <i>Operative Neurosurgery</i> , 2020, 19, 384-392. | 0.4 | 3 |
| 27 | Molecular Alterations in Meningioangiomas Causing Epilepsy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 1043-1051. | 0.9 | 3 |
| 28 | Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 353-363. | 1.4 | 3 |
| 29 | Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint. <i>Molecular and Clinical Oncology</i> , 2022, 17, . | 0.4 | 3 |
| 30 | Letter to the Editor Regarding "The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007-2017". <i>World Neurosurgery</i> , 2020, 140, 422. | 0.7 | 1 |
| 31 | Metastatic colorectal micropapillary carcinoma presenting as lymphangitic lung carcinomatosis. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 193-197. | 0.4 | 0 |
| 32 | Commentary: The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma. <i>Neurosurgery</i> , 2021, 89, E66-E67. | 0.6 | 0 |
| 33 | RADI-05. Metastatic Neoplasm Volume Kinetics Following Two-Staged Stereotactic Radiosurgery. <i>Neuro-Oncology Advances</i> , 2021, 3, iii18-iii19. | 0.4 | 0 |
| 34 | Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. <i>Neurosurgery</i> , 2022, Publish Ahead of Print, . | 0.6 | 0 |
| 35 | Gut microbiome and neurocritically ill patients. <i>Journal of Neurocritical Care</i> , 2022, 15, 1-11. | 0.4 | 0 |